Background:: High antibody reactivity toward microbial antigens in Crohn's disease (CD) patients is predictive of a more aggressive disease course. However, few ulcerative colitis (UC) patients exhibit serologic reactivity toward microbial antigens. Mucosal expression of IFN‐γ plays a pivotal role in inflammatory bowel disease (IBD) pathogenesis. Recent genome‐wide association studies (GWAS) surprisingly link UC, but not CD, risk loci to IFNG. We recently demonstrated that mucosal T cells from IBD patients exhibit distinct patterns of IFNG methylation compared to controls. This study evaluated the relationship between IFNG methylation and serologic and clinical profiles in peripheral T cells from IBD patients.
Methods:: DNA from peripheral T cells of 163 IBD patients (91 CD and 64 UC) and 42 controls was analyzed for methylation of eight IFNG sites. Serum markers ASCA, OmpC, I2, CBir, and pANCA were measured by enzyme‐linked immunosorbent assay (ELISA). IFN‐γ secretion was measured by ELISA.
Results:: IBD patients requiring surgery exhibited reduced IFNG methylation compared to nonsurgical patients (P < 0.02). Enhancement of IFN‐γ secretion (P < 0.003), along with high antibody responses toward multiple microbial antigens (P < 0.017) in UC, but not CD, patients was correlated with decreased IFNG methylation. pANCA levels were not correlated with IFNG methylation.
Conclusions:: Levels of IFNG methylation were correlated with immune response to microbial components and expression of IFN‐γ in UC patients. Serological and epigenetic markers identify a subset of UC patients with an expression profile of a key TH1 pathogenic cytokine. These data may provide a useful tool to classify a more homogeneous subset of UC patients, allowing for improved diagnostics and targeted therapeutics. (Inflamm Bowel Dis 2011;)
1Inflammatory Bowel and Immunobiology Research Institute, Cedars‐Sinai Medical Center, Los Angeles, California
2Samuel Oschin Comprehensive Cancer Institute, Cedars‐Sinai Medical Center, Los Angeles, California
Reprints: Inflammatory Bowel and Immunobiology Research Institute, Cedars‐Sinai Medical Center, 8700 Beverly Blvd., D4063, Los Angeles, CA 90048
Received 29 March 2010; Accepted 5 April 2010
Grant sponsor: United States Public Health Service; Grant Numbers: DK043211, DK046763; Grant sponsor: Cedars‐Sinai Medical Center Inflammatory Bowel Disease Research Funds.